Roche and Blueprint Medicines Partner Again in US$1.7 B Pralsetinib Pact
By Neha Madhwani & Michelle Liu
Pharma Deals Review: Vol 2020 Issue 7 (Table of Contents)
Published: 31 Jul-2020
DOI: 10.3833/pdr.v2020.i7.2553 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Blueprint Medicines has entered into a global licensing and collaboration agreement with Roche to develop and commercialise pralsetinib for the treatment of RET-altered cancers...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS